Latest Commercialisation News

MTM Critical Metals has announced a breakthrough in recovering gallium and germanium from semiconductor waste using its proprietary Flash Joule Heating technology, achieving recovery rates that rival traditional methods while offering a more sustainable and scalable solution.

Lefroy Exploration has partnered with BML Ventures under a profit-sharing agreement to develop the Lucky Strike gold deposit, aiming to start mining operations in the second half of 2025. This collaboration leverages BML's mining expertise and funding, while Lefroy retains half the profits from the project.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

Clarity Pharmaceuticals has expanded its breast cancer pipeline by introducing 64/67Cu-SAR-trastuzumab, supported by promising pre-clinical data and a new supply agreement for trastuzumab, aiming to address the unmet needs in HER2-positive breast cancer treatment.

Amaero has completed a A$22 million institutional placement, concluding nearly A$100 million raised since 2022 and positioning itself for commercialisation in FY2026 with a robust balance sheet.

ABx Group and Core Refining have mutually terminated their licence agreement as ABx pivots to a more cost-effective and sustainable method for producing aluminium fluoride, advancing the ALCORE project into its continuous pilot phase in Tasmania.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.

Micro-X has raised $3.3 million through a placement and institutional entitlement offer, reinforcing its strategic shift towards medical imaging technologies. A retail entitlement offer aiming to raise an additional $2.7 million will open shortly, supporting the company’s development of mobile X-ray and CT products.

Nanoveu Limited has completed the strategic acquisition of Embedded A.I. Systems Pte. Ltd. (EMASS), positioning itself at the forefront of ultra-low-power AI-driven edge semiconductor solutions. This move aims to enhance its EyeFly3D™ platform and expand into rapidly growing markets such as wearables, IoT, and autonomous devices.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.